Discount makes Shire's Vpriv cost-effective Gaucher for Scotland
This article was originally published in Scrip
Scotland's health technology assessment body, the Scottish Medicines Consortium, has accepted Shire's Gauchers disease drug VPRIV (velaglucerase alfa) for use on the Scottish NHS. The company was able to convince the consortium that VPRIV was cost-effective compared to its rival, Genzyme's Cerezyme, thanks to a patient access scheme.
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.